Who are HUACHANSU PIAN's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xueshuantong lyophilized powder, Standard treatment+Xiyanping injection, Erigeron breviscapus injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/huachansu-pian.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

HUACHANSU PIAN — Competitive Intelligence Brief

HUACHANSU PIAN (HUACHANSU PIAN) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Traditional Chinese medicine extract; natural product. Area: Oncology.

phase 3 Traditional Chinese medicine extract; natural product Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HUACHANSU PIAN (HUACHANSU PIAN) — Beijing Shenogen Biomedical Co., Ltd. Huachansu is a traditional Chinese medicine extract derived from toad secretions that contains bufadienolides and other bioactive compounds with potential anti-tumor and immunomodulatory properties.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
HUACHANSU PIAN TARGET	HUACHANSU PIAN	Beijing Shenogen Biomedical Co., Ltd	phase 3	Traditional Chinese medicine extract; natural product
Xueshuantong lyophilized powder	Xueshuantong lyophilized powder	Dongzhimen Hospital, Beijing	marketed	Traditional Chinese medicine extract
Standard treatment+Xiyanping injection	Standard treatment+Xiyanping injection	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	marketed	Traditional Chinese medicine extract
Erigeron breviscapus injection	Erigeron breviscapus injection	Guangzhou University of Traditional Chinese Medicine	marketed	Traditional Chinese medicine extract; antiplatelet/microcirculation enhancer

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Traditional Chinese medicine extract; natural product class)

Beijing Shenogen Biomedical Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HUACHANSU PIAN — Competitive Intelligence Brief. https://druglandscape.com/ci/huachansu-pian. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab